Background: Diagnosing coeliac disease (CD) can be challenging, despite highly specific autoantibodies and typical mucosal changes in the small intestine. The T-cell response to gluten is a hallmark of the disease that has been hitherto unexploited in clinical work-up. Objectives: We aimed to develop a new method that directly visualizes and characterizes gluten-reactive CD4þ T cells in blood, independently of gluten challenge, and to explore its diagnostic potential. Methods: We performed bead-enrichment of DQ2.5-glia-a1a and DQ2.5-glia-a2 tetramerþ cells in the blood of control individuals, treated (TCD) and untreated patients (UCD). We visualized these cells by flow cytometry, sorted them and cloned them. We assessed their specificity by antigen stimulation and re-staining with tetramers. Results: We detected significantly more gliadin-tetramerþ CD4þ effector memory T cells (T EM ) in UCD and TCD patients, compared to controls. Significantly more gliadin-tetramerþ T EM in the CD patients than in controls expressed the guthoming marker integrin-b7. Conclusion: Quantification of gut-homing, gluten-specific T EM in peripheral blood, visualized with human leukocyte antigen (HLA) -tetramers, may be used to distinguish CD patients from healthy individuals. Easy access to gluten-reactive blood T cells from diseased and healthy individuals may lead to new insights on the disease-driving CD4þ T cells in CD.
Introduction
Coeliac disease (CD) is an inflammatory condition of the small intestine caused by intolerance to proline-and glutamine-rich cereal gluten proteins. 1 In wheat, gluten consists of several hundred distinct but similar proteins that can be classified into gliadins and glutenins. 2 CD is often detected after demonstration of autoantibodies specific for the enzyme transglutaminase 2 (TG2). 3 Children can be diagnosed with CD if the TG2 antibody titer is high, added by further laboratory tests 4 ; however, in adults, duodenal biopsy and detection of typical histological changes remains a diagnostic premise. 5 Despite clear diagnostic criteria, 5 diagnosing CD can be difficult and false negative tests are a problem. Autoantibodies can be present in tissues only, but not detectable in blood. 6 In other instances, the diagnosis cannot be made because of minor or no changes in the duodenal mucosa, despite elevated TG2 antibodies. 7 Some of these individuals will develop further histological changes and overt disease that can only be diagnosed if gastroduodenoscopy is repeated. 7 The T-cell response to gluten is essential in the immunopathogenesis of CD. 8 CD4þ T cells that recognize distinct gluten epitopes in the context of the disease-associated human leukocyte antigen (HLA) molecules DQ2.5, DQ8 and DQ2.2 can be detected in the gut mucosa of CD patients, but not of healthy controls. 9, 10 For HLA-DQ2.5, which is expressed by the great majority of CD patients, two epitopes of a-gliadin (DQ2.5-glia-a1a and DQ2.5-glia-a2) are among the immunodominant epitopes. 11 Monitoring of the T-cell response to gluten has not been applied in the diagnostic work-up of CD patients. The clinical value of detecting gluten-reactive T cells in the gut of CD patients 9, 12 is limited by the need of a gastroduodenoscopy. CD4þ T cells recognizing CDrelevant epitopes can also be detected in peripheral blood mononuclear cells (PBMC) using enzyme-linked immunospot-or tetramer-based assays; however, this has so far only been possible in treated CD patients (TCD) after a 3-day oral gluten-challenge. 13, 14 Notably, gluten-specific T cells are not detectable above background in healthy controls, untreated CD patients (UCD) or TCD without gluten-challenge.
In the current study, we did bead-enrichment of gliadin-tetramerþ cells to increase the sensitivity for detection of gluten-reactive T cells. By doing so, we were able to track CD4þ T cells reactive to DQ2.5-glia-a1a and DQ2.5-glia-a2 of three T-cell subsets: naı¨ve (T N ), central memory (T CM ) and effector memory (T EM ) cells. T N are preimmune cells that can differentiate into memory T cells, if encountering a corresponding antigen. Memory T cells are categorized by homing markers and cytokine production into T EM that act at the site of inflammation, and T CM that can migrate to lymphoid tissues. 15 We found significantly more gliadin-tetramerþ CD4þ T EM in the blood of CD patients than controls. These cells were gut-homing and were found in larger numbers in CD patients with severe duodenal changes, compared to CD patients with normal mucosa. The protocol gives easy access to gluten-reactive T cells from affected and healthy individuals. Further studies on these cells may extend our understanding of one of the key players in CD pathogenesis. Our findings demonstrated that this T-cell based, minimally invasive, ex-vivo assay has potential in the diagnosis of CD.
Methods

Subjects and ethical aspects
As detailed in Table 1 , 20 UCD, 18 TCD and 16 control individuals acceded to the study. They were genomically HLA-typed and we report only the commonly CD-associated HLA-types (DQ2.5 ¼ DQA1*05 and DQB1*02; DQ2.2 ¼ DQA1*02 : 01 and DQB1*02; and DQ8 ¼ DQA1*03 and DQB1*03 : 02). We obtained blood from 14 DQ2.5þ controls through the blood bank at Oslo University Hospital, Norway. These individuals were anonymous. We have no data on their diet, biomarkers or clinical state; but diagnosed CD is an exclusion criterion for blood donation. All other participants were patients who, after giving informed written consent, donated additional blood for research purposes in conjunction to duodenal biopsies and routine clinical follow-up at the Oslo University Hospital. Patients were diagnosed according to statements from the American Gastroenterological Association (AGA). 5 Each TCD had been on a gluten-free diet (GFD) for 3 months or more. The study was approved by the regional ethics committee (S-97201).
Tetramers
Soluble, biotinylated DQ2.5 (DQA1*05 : 01, DQB1*02 : 01) molecules covalently linked with the gluten-derived T-cell epitopes DQ2.5-glia-a1 a (QLQPFPQPELPY, with underlined 9mer core sequence) or DQ2.5-glia-a2 (PQPELPYPQPE) were multimerized on phycoerythrin (PE)-labeled streptavidin (Invitrogen) or allophycocyanin (APC)-labeled streptavidin (ProZyme). 16 Cells were incubated with the tetramers (300 ml; 10 mg/ml each) at room temperature, for 40 minutes.
Cell enrichment
We obtained 50-100 ml of citrated full blood, or 60 ml of citrated buffy coat produced from 450 ml of full blood, from each participant. We isolated the PBMC by density gradient centrifugation (Lymphoprep; Axis-Shield), and further handled in a buffer containing phosphate-buffered saline (PBS), 1 mM ethylenediaminetetraacetic acid (EDTA) and 1% human serum.
We followed an established protocol for enrichment of tetramer-positive cells. 17 Briefly, PBMC were counted and incubated with FcR blocking reagent (Miltenyi Biotec) before the PE-and APC-conjugated tetramers were added. The cells were washed and a small fraction removed for later staining as a 'preenriched sample' before we added the anti-PE-and anti-APC microbeads (Miltenyi Biotec). We then washed the cells, re-counted them and passed them over a magnetized column (MS or LS column, Miltenyi Biotec). We collected the cells that did not bind the column as 'depleted cells'.
Flow cytometry
The enriched cells were eluted and all samples were stained 20 minutes on ice at a volume of 25 ml. The following antibodies were used: CLA-FITC, Integrin-b7-PE, CD62L-PerCP/Cy5.5, CD14-Pacific blue, CD19-Pacific blue, CD56-Pacific blue, CD11c-V450, CD4-APC-H7 (all from BD Biosciences); as well as CD45RA-PE-Cy7 and CD3-eFluor605 (both from eBioscience). We washed and analyzed the cells on a LSR II (BD Biosciences) or sorted on a FACS Aria I cell sorter (BD Biosciences). The entire enriched samples were run through, in order to enumerate all tetramer-positive cells.
Cells binding the DQ2.5-glia-a1a-or the DQ2.5-glia-a2-tetramer were identified as relevant if they were: CD3þ, CD11c-, CD14-, CD19-, CD56-and CD4þ. Relevant gliadin-tetramerþ cells were sub-divided into and sorted as CD45RAþ/CD62Lþ cells (T N ), CD45RA-/CD62L-cells (T EM ) and CD45RA-/ CD62Lþ cells (T CM ) (see Figure 1 (a) and Figure  1 (b)). 18 Integrin-b7 staining was performed in four controls and four TCD; and cutaneous leucocyte-associated antigen (CLA) staining in one TCD (see Figure 4 ).
We calculated the frequencies of gliadin-tetramerþ cells as follows:
Gliadin-tetramer positive cells in the enriched sample
Total number of CD4-positive T cells
The total number of CD4þ T cells was calculated by multiplying the fraction of CD4þ T cells stained in the pre-enriched sample with the total number of counted PBMC. We used FlowJo software (Tree Star) for analysis of flow data.
Culturing and screening of sorted cells
The sorted cells were cloned by limited dilution and expanded without antigens, as previously described. 19 
Table 1. Characteristics of participants
Participant Category a HLA-type 
Patients P1-P10 and P13-P16 were anonymous blood bank donors. b UCD were usually referred to gastroduodenoscopy with IgA anti-TG2 above cut-off. These values refer to the repeated sample at time of endoscopy. c The mucosal changes were only asserted in the bulbus duodeni, in this participant. d The gliadin-tetramer-staining was combined on one fluorochrome. EM/N-ratio: the ratio between gliadin-tetramerþ CD4þ effector memory and naïve T cells; HLA: human leukocyte antigen; IgA: immunoglobulin A; ND: not done; P: participant; TCD: treated coeliac disease; UCD: untreated coeliac disease.
Growing T-cell clones (TCC) were tested both in a T-cell proliferation assay and by re-staining with gliadin-tetramers. We analyzed the tetramer-stained cells on a FACS Calibur (BD Biosciences) ( Supplementary Figure 1 ). Cells showing a clear shift in staining-intensity with the DQ2.5-glia-a1a-tetramer compared to the DQ2.5-glia-a2-tetramer and the unstained control were identified as specific for the DQ2.5-glia-a1a-peptide, and vice versa. We used a well-established protocol for antigendependent T-cell proliferation. 19 Briefly, we used DQ2.5 homozygous Epstein-Barr virus (EBV)-transformed cells (IHW #9023) presenting the DQ2.5-glia-a1a-epitope peptide (QLQPFPQPELPY, underlined 9mer core sequence) or a peptide containing the DQ2.5-glia-a2-epitope (PQPELPYPQPQL) (both from Research Genetics). The final peptide concentration was 10 mM. We assessed T-cell proliferation by thymidine incorporation. 19 The TCC that dispalyed a stimulation index (SI) above three, calculated by dividing counts per minute (cpm) after antigen stimulation with cpm after medium stimulation, were identified as peptide-specific.
Statistical analysis
We used the GraphPad Prism 5 software for statistical analysis and the Mann-Whitney U test to calculate statistical significance.
Results
Visualizing gluten-specific T cells in peripheral blood
Motivated by a protocol that can detect rare epitopespecific naı¨ve CD4þ T cells by tetramer-staining and bead-enrichment, 17 we aimed to identify CD4þ T cells that are reactive to the two dominant gluten-epitopes, DQ2.5-glia-a1a and DQ2.5-glia-a2, in blood from DQ2.5þ controls, UCD and TCD (Table 1) without oral gluten challenge. We used strict gating for identification of gliadin-tetramerþ CD4þ T cells ( Figure  1(a) ) and subpopulations of these cells (Figure 1(b) ).
In all but one control subjects, we identified relatively few gliadin T CM or T EM and a distinct population of gliadin-tetramerþ CD4þ T N . In control subject P2, we found a large number of gliadin-tetramerþ CD4þ T EM , similar to levels found in UCD patients. We suspected that subject P2 had CD that was undiagnosed; however, as this participant was an anonymous blood donor, we were unable to do any clinical examination. This subject and the other blood bank donors were all included in the group of control individuals. We also observed some gliadin-tetramerþ CD4þ T cells in non-HLA-DQ2.5 subjects (Supplementary figures 2(a) and 2(b)), similar to what has been observed with other HLA II tetramers. 20 Validating the gluten specificity of tetramerþ T cells Gliadin-tetramerþ CD4þ T N , and in some cases also T EM and T CM from six controls, two UCD and five TCD were sorted, cloned by limiting dilution and cultured in an antigen-independent manner. The success rate of generating TCC from sorted T cells differed substantially between the subjects. On average, we cultured growing TCC from one-fourth of sorted cells ( Table 2 ). Each generated TCC was assayed for proliferative response to the DQ2.5-glia-a1a-and the DQ2.5glia-a2-epitope. We found that 122/163 T EM , 4/20 T CM and 76/193 T N clones responded to the epitope (with a SI ! 3) of the tetramer for which they originally were isolated. Gliadin-tetramerþ T CM and T EM cells from subject P40 were sorted together and 23/30 of these clones were specific in the T-cell assay ( Supplementary Figure 2(a) ). All TCCs that gave specific responses in T-cell assays had a clear and specific staining with the corresponding tetramer. Five T EM and 30 T N clones showed poor proliferation (SI < 3), despite clear tetramer staining. Twelve of the co-sorted T EM and T CM clones from subject P40 also held this feature.
The frequency of gluten-specific T cells in peripheral blood
The frequency of CD4þ DQ2.5-glia-a1a-and the DQ2.5-glia-a2-tetramerþ cells was similar among the three participant groups for T N (respective median frequency 0.61 and 0.94 per million total CD4þ T cells) and T CM (respective median frequency 0.29 and 0.49 per million CD4þ T cells) ( Figure 2 ). In contrast, there was a significantly higher frequency of gliadintetramerþ CD4þ T EM in UCD, as compared to controls (p < 0.0001 for both tetramers) and in TCD compared to controls (p < 0.0001 and p ¼ 0.0002) ( Table 1 and Figure 3(a) ). The frequency of T EM binding either gliadin-tetramer was <0.4 per million total CD4þ T cells in control subjects. In comparison, the corresponding frequencies were !1 in 18 out of 19 HLA-DQ2.5þ UCD and 11 out of 13 HLA-DQ2.5þ TCD.
The EM/N ratio in patients and controls
In order to get a simpler and more robust parameter for the T-cell response to gluten, we divided the number of T EM by the number of T N (termed the EM/N ratio). We found this parameter more useful, as it is independent of the number of total CD4þ T cells. For both epitopes studied, we observed significant differences in the EM/N ratio between controls (all with a ratio <1, except for subject P2) and UCD (all with a ratio >1, except for subject P24), and between controls and TCD (15 out of 17, with a ratio >1 for one or both of the tetramers), as seen in Table 1 and Figure 3(b) ).
Gluten-specific T EM versus duodenal changes
The histological appearance in the duodenal mucosa can be graded into normal mucosa (Marsh score 0), increased numbers of intraepithelial lymphocytes (Marsh score 1), hyperplastic lesion and crypt Table 2 shows the percentage of sorted EM, CM and N type T cells successfully expanded by the antigen-independent cloning and the number of specific TCC, as defined by specific re-staining, of the total number of growing TCC. In this table, CD4þ T cells binding the DQ2.5-glia-a1a-or the DQ2.5-glia-a2tetramer are merged. a T EM and T CM were sorted into one tube. CM: Central memory; EM: effector memory; N: naïve T cells; ND: not done; P: participant; TCC: T-cell clones; TCD: treated coeliac disease; UCD: untreated coeliac disease.
hyperplasia (Marsh score 2), and variable degrees of villous blunting (Marsh score 3). 21, 22 It is poorly understood how histological changes related to gluten ingestion develop, but gluten-specific CD4þ T cells are thought to play a crucial role. 9, 10, 12 We looked at whether the observed variations in the frequency of gliadin-tetramerþ CD4þ T EM in peripheral blood correlated with the Marsh score of CD patients at the time of blood analysis (Figure 3(c) ). We found a significantly higher frequency of DQ2.5-glia-a1a and DQ2.5-glia-a2 -specific CD4þ T EM in participants with a Marsh score 3, compared to those with a Marsh score 0.
Very few of our CD patients had Marsh score 2 and the frequency of gliadin-tetramerþ cells among these was variable.
Gut homing of gluten-specific T EM
A few CD patients had either frequencies of gliadintetramerþ T EM or an EM/N ratio similar to controls. To test whether patients and controls could be further distinguished, we analyzed CD4þ gliadin-tetramer positive versus negative cells in four TCD and four controls, for the gut-homing marker integrin-b7 in the population of cells obtained after tetramer bead enrichment (Figure 4 (a) and Figure 4(b) ). In TCD, significantly more gliadin-tetramerþ T EM (80-95%), compared to gliadin-tetramer-cells, expressed integrin-b7. In contrast, integrin-b7 expression did not exceed background in the gliadin-tetramerþ T EM of controls.
Integrin-b7 forms gut-homing dimers with a4or a Esubunits; and a skin-homing dimer with the a1 chain. Peripheral blood from one TCD was stained for the CLA. None of the gliadin-tetramerþ T EM in this TCD expressed the skin-homing marker (Figure 4(c) ), indicating that the observed integrin-b7 expression is associated with gut-homing rather than skin-homing.
Discussion
We here demonstrate that gluten-reactive T cells in peripheral blood can be characterized and enumerated directly ex vivo in TCD, UCD and controls without oral gluten challenge. Gut-homing gliadin-tetramerþ CD4þ T EM were significantly more frequent in CD patients than controls. These cells likely reflect an antigendriven, CD-associated T-cell response, and there is a potential for using this parameter for the diagnostic work-up of CD. All UCD and TCD had either a ratio of T EM /T N cells >1 or a frequency of T EM specific for one or both of the epitopes DQ2.5-glia-a1a or DQ2.5-glia-a2 > 1 per million total CD4þ T cells. The only exception was TCD P50 (EM/N ratio 0.3). Still, the gliadin-tetramerþ T EM of this treated patient expressed integrin-b7 significantly above background and thus, is distinguishable from the tetramerþ T EM of controls. In comparison, all controls (except P2) had both the EM/ N ratio <0.8 and the frequency of gliadin-tetramerþ T EM < 0.4 per million total CD4þ T cells. We strongly suspect that the anonymous donor P2 had undiagnosed CD. The combination of integrin-b7þ T EM percentage with the EM/N ratio seemed to give a good discrimination of patients versus controls. This notion must be corroborated in future studies.
GFD will often normalize diagnosis-dependent parameters like histology and disease-specific antibodies in CD patients. 23 Still, proliferating intraepithelial lymphocytes, 24 duodenal TG2-specific antibody-secreting cells 25 and duodenal gluten-specific T cells can be detected in TCD. 9 These data indicate a persistent immune response to gluten in many TCD. Our finding supports this notion, as gliadin-tetramerþ EM cells were detected in the blood of all included TCD, despite normal mucosa and negative antibody titers in many of them. The persistent T-cell response to gluten in TCD may be explained by long-lived memory T cells, 26 local IL-15 production 27 or sporadic exposure to small amounts of gluten antigen. Importantly, we are able to detect a persistent T-cell response in blood that can prove to be very helpful in diagnosing patients that are already on a GFD, without previously confirmed CD diagnosis.
Notably, we found a statistically significant difference in T EM numbers between CD patients with Marsh score 0 and 3, despite the small group sizes and the issue of CD lesion patchiness. 28 Although gluten-specific T cells may not be directly responsible for the remodeling of the intestinal mucosa, they can drive inflammation through pro-inflammatory mediators that activate intraepithelial cytotoxic T lymphocytes. 29 As gliadin-tetramerþ T EM cells in the blood of CD patients show high expression of gut-homing markers and use T-cell receptors typical of CD lesionderived T cells, 30 they likely have intestinal origin and reflect the disease-driving gluten-reactive T-cell response in the lamina propria. Whether the latter is the case could be further tested in studies where the T-cell receptor sequences of intestinal and peripheral blood gliadin-tetramerþ cells are compared.
The rate of the proliferative response to peptide stimulation seemed to be phenotype-dependent. In general, the fraction of TCC proliferating after peptide stimulation was lower among T EM from controls, T N from CD patients and T CM overall. Notably, we were not able to confirm gluten reactivity of the few gliadintetramerþ memory cells of our controls, except for two T CM clones. One might speculate that tetramerþ T EM from controls represent gluten-specific regulatory T cells or some other T-cell phenotypes that do not necessarily respond to antigen stimulation with proliferation. Overall, poor yield of specific tetramer-sorted blood cells could possibly be explained by tetramer-induced cell apoptosis 31 and by a certain degree of background staining. 32 Nevertheless, we believe that this protocol can be used in further studies on gluten-reactive T cells of CD patients and controls, give important insights into CD pathogenesis and accommodate a search for disease-specific T-cell receptors. 33 CD patients can present with histological changes in the small intestine, but negative serology, 6 and vice versa. 7 This has led to an ongoing debate on the diagnostic criteria for CD. 7, 34 A large number of individuals are also on a GFD without any confirmed CD diagnosis 35 reducing the sensitivity of currently available diagnostic tools substantially.
We report a significant difference in the number of gluten tetramerþ T EM in UCD and TCD, and in the gut-homing of these cells in CD patients compared to controls without performing a gluten challenge. Flow cytometry is already routinely used in clinical work-up. The current protocol allows analysis with 50 mL of blood; and this volume may be further reduced, if gluten epitopes are combined. Tetramerized HLA-DQ8-and HLA-DQ2.2-restricted gluten epitopes should also be tested with the current approach, to include also these minor groups of CD patients. Moreover, HLA tetramer production may be optimized in an industrial setting, with production costs similar to other diagnostic assays. Thus, we will argue that this minimally invasive, ex-vivo method may find use in clinical practice, particularly in patients with vague diagnostic conditions, or in cases where a gastroduodenoscopy is inappropriate or undesirable, as well as in undiagnosed individuals adhering to a GFD.
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